Physician profile

Jack Levy

MOHS-Micrographic Surgery · New York, NY

NPI 1720512049

$226.26

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$88.35

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $46.62 2021-2023 Otezla
Sanofi Pasteur INC. $26.67 2022
Mayne Pharma Commercial LLC $22.12 2023
Biofrontera INC. $21.49 2022
Almirall LLC $19.43 2023 Seysara
Journey Medical Corporation $18.16 2022
Kyowa Kirin, INC. $16.02 2023 Poteligeo
Lilly USA, LLC $14.76 2022
Regeneron Healthcare Solutions, INC. $13.92 2023 Dupixent
Ortho Dermatologics, A Division of Bausch Health US, LLC $13.75 2021
Ucb, INC. $13.32 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jack Levy

$226.26

in general payments reported 2019-2025

Years
2021-2023
Top company
Amgen INC.

https://glasscript.com/doctor/11291164/jack-levy

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.